Up to 70% of patients experience postoperative recurrence within a year of ileocolonic resection for Crohn's disease, and the field has treated that as a separate problem from disease onset. This review advances a different hypothesis: that the transient disease-free state after resection biologically mirrors the earliest preclinical stage of new-onset disease, and that the two settings share pathogenic pathways.
The authors assemble biomarker and multiomics evidence from both kinds of cohort and name the overlaps — genetic variants, immune mediators including CXCL9 and interleukin 6, microbial signatures involving Faecalibacterium and Ruminococcus, and markers of gut barrier dysfunction and systemic inflammation. They also survey emerging approaches, glycomics, urine metabolomics and high-dimensional immunophenotyping, as ways to refine risk stratification.
The argument that matters is practical rather than mechanistic. Preclinical Crohn's disease cannot easily be studied, because you cannot identify the people who are about to develop it. The postoperative setting gives you a defined cohort, a known start date and a one-year event rate of up to 70% — which makes it a pragmatic human model for testing biomarker-guided prevention that could then apply across the disease spectrum. Nothing here changes what you do after a resection today; what it changes is where the trials should be run.
- Continue current postoperative recurrence prophylaxis and colonoscopic assessment — nothing here supersedes it
- Record the resection date precisely; it is the start of the window this argument is about
- Treat the biomarkers named as candidates under study, not as tests to order
- Expect biomarker-guided prevention trials to recruit in the postoperative setting first
- Note that up to 70% recur within a year — worth stating plainly when consenting for surgery
Why it matters
It reframes postoperative recurrence as an accessible model for studying how Crohn's disease begins at all.
Don't overread it
This is a narrative review proposing a hypothesis — the shared biomarkers are candidates, not validated predictors.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free